BioAge Labs, Inc 10-Q for FY2026 Q3
BioAge Labs, Inc. (BIOA)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
BioAge Labs, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
BioAge dosed first participants in QUELL-CV and QUELL-DME Phase 2 trials in June 2026 and September 2026. At September 30, 2026, it held $352.3 million in cash, cash equivalents, and marketable securities and expects funding through 2029. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $298K
- down 85.5% from $2.05M a year earlier
- Net loss
- $33.5M
- compared with a net loss of $20.17M a year earlier
- Diluted EPS
- -$0.73
- compared with -$0.56 a year earlier